Paper Details

  1. Home
  2. Paper Details

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.

Author: AmareM, BonnetJ D, DixonD O, DurieB G, HautA, SalmonS E, WeickJ K

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A study of 237 patients with multiple myeloma found that alternating combination chemotherapy was more effective than melphalan-prednisone in achieving remission and improving survival. Adding levamisole to maintenance chemotherapy also improved survival.
Paper Details　
Original Abstract of the Article :
Previously untreated patients with multiple myeloma were entered on a randomized clinical trial to determine whether the use of alternating combination chemotherapy, including vincristine, doxorubicin, alkylating agents, and prednisone (160 patients) was more effective than conventional chemotherapy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1983.1.8.453

データ提供：米国国立医学図書館（NLM）

Alternating Combination Chemotherapy and Levamisole: A Promising Approach for Multiple Myeloma

Multiple myeloma, a complex hematologic malignancy, presents significant challenges for treatment. This research investigates the effectiveness of alternating combination chemotherapy and levamisole in improving survival for patients with multiple myeloma. The study, conducted by the Southwest Oncology Group, compared two treatment groups: one receiving alternating combination chemotherapy (including vincristine, doxorubicin, alkylating agents, and prednisone) and the other receiving conventional chemotherapy with melphalan and prednisone.

Enhanced Remission and Improved Survival

The results demonstrated that the more aggressive alternating combination chemotherapy was significantly more effective in inducing remission, with a higher proportion of patients achieving at least 75% tumor mass regression. Furthermore, patients receiving alternating combination chemotherapy experienced a longer median survival compared to those receiving melphalan-prednisone. The study also revealed that adding the immunomodulating agent levamisole to maintenance chemotherapy further enhanced survival in patients who achieved remission.

The Promise of a More Effective Treatment Strategy

These findings provide compelling evidence for the use of aggressive multiagent chemotherapy for remission induction in patients with advanced-stage multiple myeloma. The study suggests that incorporating levamisole into maintenance chemotherapy may offer additional benefits in improving survival rates. This research represents a crucial step forward in understanding the effectiveness of different treatment strategies for multiple myeloma.

Dr.Camel's Conclusion

This study highlights the importance of exploring new and innovative treatment strategies for multiple myeloma, with the goal of improving patient outcomes. Imagine the desert of multiple myeloma as a vast and challenging landscape. This research provides a new oasis, offering a more effective treatment approach that could lead to longer and healthier lives for patients.
Date :
  1. Date Completed 1984-04-13
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

6366141

DOI: Digital Object Identifier

10.1200/JCO.1983.1.8.453

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.